Torie Grant1, Jennifer Dantzer1, Corinne Keet1, Roger Peng2, Beverly J Paigen3, Mary Krevans3, Karol Hagberg3, Jean Curtin-Brosnan1, Wayne Shreffler4, Elizabeth C Matsui1. 1. From the Division of Pediatric Allergy/Immunology, Johns Hopkins School of Medicine, Baltimore, Maryl. 2. Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryl. 3. The Jackson Laboratory, Bar Harbor, Maine. 4. Divsions of Allergy and Immunology, Department of Pediatrics, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Abstract
BACKGROUND: The disrupted skin barrier in eczema has been associated with an increased risk of immunoglobulin E (IgE) sensitization in childhood. However, it is unclear whether eczema, independent of atopy, is a risk factor for the development of allergic sensitization in adulthood. OBJECTIVE: To determine if skin barrier dysfunction, independent of atopy, is a risk factor for incident sensitization in adult workers at a mouse production and research facility. METHODS: New employees at The Jackson Laboratory enrolled in a cohort study and underwent skin-prick testing (SPT) at baseline and every 6 months to mouse and to a panel of aeroallergens (net wheal ≥3 mm indicated a positive SPT result). Mouse allergen exposure was measured every 6 months by using personal air monitors. Physician-diagnosed eczema was defined as self-reported physician-diagnosed eczema. Cox proportional hazard modeling was used to examine the association between baseline physician-diagnosed eczema and incident mouse skin test sensitization and adjusted for potential confounders. RESULTS: The participants (N = 394) were followed up for a median of 24 months. Fifty-four percent were women, 89% were white, and 64% handled mice. At baseline, 7% of the participants reported physician-diagnosed eczema and 9% reported current asthma; 61% had at least one positive skin test result. At 30 months, 36% of those with eczema versus 14% of those without eczema had developed a positive mouse skin test result (p = 0.02, log-rank test). After adjusting for age, race, sex, smoking status (current, former, never), current asthma, hay fever, the number of positive SPT results at baseline, and mouse allergen exposure, physician-diagnosed eczema was an independent risk factor for incident mouse SPT sensitization (hazard ratio 5.6 [95% confidence interval, 2.1-15.2]; p = 0.001). CONCLUSION: Among adult workers at a mouse production and research facility, physician-diagnosed eczema was a risk factor for incident mouse sensitization, independent of atopy, which indicated that a defect in skin barrier alone may increase the risk of skin sensitization, not just in childhood, but throughout life.
BACKGROUND: The disrupted skin barrier in eczema has been associated with an increased risk of immunoglobulin E (IgE) sensitization in childhood. However, it is unclear whether eczema, independent of atopy, is a risk factor for the development of allergic sensitization in adulthood. OBJECTIVE: To determine if skin barrier dysfunction, independent of atopy, is a risk factor for incident sensitization in adult workers at a mouse production and research facility. METHODS: New employees at The Jackson Laboratory enrolled in a cohort study and underwent skin-prick testing (SPT) at baseline and every 6 months to mouse and to a panel of aeroallergens (net wheal ≥3 mm indicated a positive SPT result). Mouse allergen exposure was measured every 6 months by using personal air monitors. Physician-diagnosed eczema was defined as self-reported physician-diagnosed eczema. Cox proportional hazard modeling was used to examine the association between baseline physician-diagnosed eczema and incident mouse skin test sensitization and adjusted for potential confounders. RESULTS: The participants (N = 394) were followed up for a median of 24 months. Fifty-four percent were women, 89% were white, and 64% handled mice. At baseline, 7% of the participants reported physician-diagnosed eczema and 9% reported current asthma; 61% had at least one positive skin test result. At 30 months, 36% of those with eczema versus 14% of those without eczema had developed a positive mouse skin test result (p = 0.02, log-rank test). After adjusting for age, race, sex, smoking status (current, former, never), current asthma, hay fever, the number of positive SPT results at baseline, and mouse allergen exposure, physician-diagnosed eczema was an independent risk factor for incident mouse SPT sensitization (hazard ratio 5.6 [95% confidence interval, 2.1-15.2]; p = 0.001). CONCLUSION: Among adult workers at a mouse production and research facility, physician-diagnosed eczema was a risk factor for incident mouse sensitization, independent of atopy, which indicated that a defect in skin barrier alone may increase the risk of skin sensitization, not just in childhood, but throughout life.
Authors: Roger D Peng; Beverly Paigen; Peyton A Eggleston; Karol A Hagberg; Mary Krevans; Jean Curtin-Brosnan; Cristy Benson; Wayne G Shreffler; Elizabeth C Matsui Journal: J Allergy Clin Immunol Date: 2011-06-22 Impact factor: 10.793
Authors: Päivi M Salo; Samuel J Arbes; Renee Jaramillo; Agustin Calatroni; Charles H Weir; Michelle L Sever; Jane A Hoppin; Kathryn M Rose; Andrew H Liu; Peter J Gergen; Herman E Mitchell; Darryl C Zeldin Journal: J Allergy Clin Immunol Date: 2014-02-09 Impact factor: 10.793
Authors: M I Asher; U Keil; H R Anderson; R Beasley; J Crane; F Martinez; E A Mitchell; N Pearce; B Sibbald; A W Stewart Journal: Eur Respir J Date: 1995-03 Impact factor: 16.671
Authors: C Flohr; K England; S Radulovic; W H I McLean; L E Campbel; J Barker; M Perkin; G Lack Journal: Br J Dermatol Date: 2010-12 Impact factor: 9.302